Building the ctDNA Blueprint: A Cross-Functional Strategy to Advance Oncology Drug Development

• ctDNA as a predictive marker for therapeutic response and a potential surrogate for survival outcomes, enabling faster, more efficient trial designs
• ctDNA as an early, sensitive marker for tracking tumor burden and minimal residual disease (MRD), allowing for earlier intervention and better monitoring of disease progression
• Longitudinal ctDNA analysis for determining biologically active dosages, allowing for adjustments in dosage regimens to maximize efficacy while minimizing toxicity

Speakers:

Raluca Budiu-Predoiu

Director, Precision Medicine

Abbvie

Emily Rossi

Senior Scientist II, Quantitative Medicine & Genomics

Abbvie